This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07351058 |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Hoffmann-La Roche |
| Enrollment | 1,600 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity or Overweight; Type 2 Diabetes Mellitus |
| Interventions | Placebo; Enicepatide |
| Start | Mar 23, 2026 |
| Primary completion | Aug 7, 2028 |
| Study completion | Aug 7, 2028 |
| Results posted | Not yet |
| Registry last updated | Sep 14, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent (%) Change from Baseline in Body Weight at Week 72 | Baseline through Week 72 |
40 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
